Vertex lays off 370, focuses on cystic fibrosis

Share this article:

Flagging Incivek sales have prompted Vertex to slash 370 jobs. Bloomberg reports that the company's hepatitis C drug has lost out to competitors as new drugs have entered the marketplace, and anticipated newer drugs, such as Gilead's sofosbuvir, have dampened enthusiasm for the treatment. Bloomberg notes Vertex's peak Incivek sales happened in the fourth quarter of 2011 and have been declining since. The cuts amount to 15% of the company's workforce.

The company said in a third-quarter earnings statement that it will focus on cystic fibrosis.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.